Likewise, there was an increase of monocytes expressing HLA-DR as well as of intermediate monocytes [49] which have been associated with clinical benefit in patients with melanoma treated with anti-PD-1 immunotherapy [26] and good prognosis in patients with breast cancer [51], respectively. Here, PDCD1 is linked to melanoma.